{
  "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "docSlug": "2296286e07283457e97b21dc9ce59469",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 46,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide uses a matrix structure to compare clinical outcomes against three key value propositions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/12",
  "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "deckJsonHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0.json",
  "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Benefits of Outpatient Therapy: Much larger accessible market/wider access to NXC-201 CAR-T; Potential 80% reduction in hospital stay costs.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36bcaf38-3d77-4a5c-9465-edf523d2f4c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.95,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: for expected recommended phase 2 dose cohort.. Source for 1% and 15 day median hospital stay: Sharma A, Singh V, Deol A. Epidemiology and Predictors of 30-Day Readmission in CAR-T Therapy Recipients. M. Assayag, et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72c5331a-e041-4237-bee0-c8dce74bc97c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.95,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "table",
      "text": "Matrix comparing Relapsed/refractory Multiple Myeloma and AL Amyloidosis across High Overall Response Rates, Favorable Tolerability, and Potential Outpatient Therapy.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03a858b1-34a9-4ae2-bedd-db27b8751827",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 Overview: Best in Class Potential in Multiple Myeloma and AL Amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b804d0d7-e63d-4768-868d-66281a18f2fa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "NxN matrix",
      "slug": "matrix-nxn",
      "agent": null,
      "layer": "slide",
      "matchId": "0dc1496b-551e-439c-a94e-1db89edd8d18",
      "evidence": "table/data: Matrix comparing Relapsed/refractory Multiple Myeloma and AL Amyloidosis",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "34b36f85-219b-48fb-8d3d-a8774c6a2759",
      "evidence": "The slide organizes clinical data into a grid comparing indications against performance metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "ec348a34-4a83-4f17-b0f0-268fe2d31e3a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation presents Immix Biopharma's solutions and clinical results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "d3ed2b4b-7476-486a-bc9e-587ba67669a2",
      "evidence": "The presentation presents clinical results and data to support the solutions.",
      "position": 1,
      "objective": "What are the potential benefits of Immix Biopharma's solutions?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}